Evaluation of Comparative Performance of Orally Inhaled Drug Products in View of the Classical Bioequivalence Paradigms: An Analysis of the Current Scientific and Regulatory Dilemmas of Inhaler Evaluation

Everard Mark

首页> 外文期刊>Journal of aerosol medicine and pulmonary drug delivery >Evaluation of Comparative Performance of Orally Inhaled Drug Products in View of the Classical Bioequivalence Paradigms: An Analysis of the Current Scientific and Regulatory Dilemmas of Inhaler Evaluation

【24h】

Evaluation of Comparative Performance of Orally Inhaled Drug Products in View of the Classical Bioequivalence Paradigms: An Analysis of the Current Scientific and Regulatory Dilemmas of Inhaler Evaluation

机译：基于经典生物等效性范式的口服药物比较性能评估：对当前吸入器评估的科学和管理难题的分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of aerosol medicine and pulmonary drug delivery》 |2014年第6期|共1页
作者
Everard Mark;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
regulatory and regulations; Inhalation drug products; risk management; bioequivalence;

机译：法规;吸入药物产品;风险管理;生物等效性;

相似文献

外文文献
中文文献
专利

1. Evaluation of Comparative Performance of Orally Inhaled Drug Products in View of the Classical Bioequivalence Paradigms: An Analysis of the Current Scientific and Regulatory Dilemmas of Inhaler Evaluation [J] . Horhota Stephen T. Journal of aerosol medicine and pulmonary drug delivery . 2014,第6期

机译：基于经典生物等效性范式的口服药物比较性能评估：对当前吸入器评估的科学和管理难题的分析
2. Bioequivalence study designs for generic solid oral anticancer drug products: Scientific and regulatory considerations [J] . KaurP., ChaurasiaC.S., DavitB.M., The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2013,第12期

机译：通用固体口服抗癌药物产品的生物等效性研究设计：科学和监管方面的考虑
3. Bioequivalence study designs for generic solid oral anticancer drug products: Scientific and regulatory considerations [J] . KaurP., ChaurasiaC.S., DavitB.M., The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2013,第12期

机译：生物等效性研究通用实体口服抗癌药品：科学和监管考虑因素
4. A Theoretical and Scientific Evaluation of the Potential to Form Sulfonic Acid Esters in Mesylate Salt Drug Substances and Drug Products [C] . Alina Domin Turza, Christopher M. McGinley, Robert J. Baker, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：对甲磺酸盐药物物质和药品形成磺酸酯的潜力的理论和科学评价
5. Meta-Analysis to Identify and Evaluate Factors Associated with Regulatory Approval of Orphan Drugs (OD) to Develop an Algorithm for Predicting Regulatory Approval (Success) and to Develop a Standardized Tool to Improve Orphan Drug Portfolio Decision-Making [D] . Florent, Milky C. 2019

机译：荟萃分析，以识别和评估与孤儿药物监管批准（OD）相关的因素，以开发预测监管批准（成功）的算法，并开发标准化工具以改善孤儿药物投资组合决策
6. Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference [O] . Guenther Hochhaus, Craig Davis-Cutting, Martin Oliver, 2015

机译：开发口服吸入和鼻用药物产品的当前科学和法规方法：IPAC-RS /佛罗里达大学奥兰多吸入会议的概述
7. Use of PBPK Modeling To Evaluate the Performance of DissolvIt, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products [O] . -1

机译：使用PBPK建模来评估溶解的性能，对口腔吸入药品的Biorelevant溶解测定
8. Deep-Sea Red Crab 2010 Fishing Year Specifications (March 1, 2010-February 28, 2011) and Stock Assessment and Fishery Evaluation (SAFE Report) Including the Environmental Assessment (EA), Regulatory Impact Review (RIR) and Initial Regulatory Flexibility Analysis (IRFA) [R] . 2011

机译：深海红蟹2010捕捞年度规格（2010年3月1日 - 2011年2月28日）和库存评估和渔业评估（saFE报告），包括环境评估（Ea），监管影响评估（RIR）和初始监管灵活性分析（ IRFa）

Evaluation of Comparative Performance of Orally Inhaled Drug Products in View of the Classical Bioequivalence Paradigms: An Analysis of the Current Scientific and Regulatory Dilemmas of Inhaler Evaluation

著录项

相似文献

相关主题

期刊订阅